Travere Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$41.4M
Doctors Paid
11,855
Transactions
63,241
2024 Total
$10.4M
Payment Breakdown by Category
Research$35.1M (84.8%)
Consulting$1.8M (4.4%)
Food & Beverage$938,824 (2.3%)
Travel$564,241 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $35.1M | 9,133 | 84.8% |
| Consulting Fee | $1.8M | 991 | 4.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 720 | 3.7% |
| Grant | $1.2M | 19 | 2.8% |
| Food and Beverage | $938,824 | 32,482 | 2.3% |
| Travel and Lodging | $564,241 | 1,860 | 1.4% |
| Education | $104,955 | 17,961 | 0.3% |
| Charitable Contribution | $48,000 | 6 | 0.1% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $45,863 | 50 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $23,200 | 8 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $20,517 | 11 | 0.0% |
Payments by Type
Research
$35.1M
9,133 transactions
General
$6.3M
54,108 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| OT-58 AS AN ENZYME THERAPY FOR PATIENTS WITH HOMOCYSTINURIA CAUSED BY CYSTATHIONINE BETA-SYNTHASE DEFICIENCY | $5.7M | 1 | 358 |
| 021FSGS16010 | $5.6M | 0 | 4,165 |
| 021IGAN17001 | $3.3M | 0 | 2,332 |
| RTRX-RE021-101 | $2.0M | 0 | 9 |
| A Phase 3, Parallel-Group Treatment, Blinded, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria Due to Cystathionine Beta Synthase Deficiency | $1.7M | 0 | 27 |
| SPARTACUS | $1.1M | 0 | 165 |
| A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases | $1.1M | 0 | 215 |
| DUET | $1.0M | 0 | 477 |
| TVTX-CHOLB-101 | $991,579 | 0 | 5 |
| An Open-Label, Phase 3 Long-Term Extension LTE Study to Assess the Safety, Tolerability, and Efficacy of treatment with Pegtibatinase in Participants with Classical Homocystinuria HCU due to Cystathionine Beta Synthase Deficiency ENSEMBLE | $942,099 | 0 | 49 |
| Pegtibatinase as an Enzyme Therapy for Patients With Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE) | $935,971 | 0 | 16 |
| NEPTUNE III project | $918,000 | 0 | 2 |
| NEPTUNE III | $918,000 | 0 | 2 |
| RTRX-RE021-103 | $899,074 | 0 | 7 |
| Pegtibatinase as an Enzyme Therapy for Patients With Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency | $850,783 | 0 | 27 |
| Protocol No: 018CTXX15001 | $525,682 | 0 | 180 |
| A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | $490,179 | 0 | 130 |
| SGLT2i DDI (TVTX-RE021-106) | $474,326 | 0 | 6 |
| NATURAL HISTORY STUDY OF HOMOSYSTINURIA CAUSED BY CYSTATHIONINE BETA-SYNTHASE DEFICIENCY | $472,530 | 0 | 99 |
| A Phase 3, Parallel-group treatment, Blinded, Randomized, Placebo-controlled in to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY). | $440,360 | 0 | 2 |
| The Replace Registry | $435,448 | 0 | 268 |
| A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous Xanthomatosis | $365,808 | 0 | 44 |
| Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (ACAPPELLA) | $359,605 | 0 | 8 |
| Protocol is CBS-HCY-NHS-01, Study Name: Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency | $355,680 | 0 | 8 |
| TVTX-RE021-106 | $280,974 | 0 | 2 |
| 024PKAN15004 | $264,581 | 0 | 37 |
| Phase 1 BE Study (TVTX-CHOLB-101) | $237,751 | 0 | 6 |
| Natural History Study of Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency | $229,794 | 0 | 32 |
| Open Label Prospective Observational Registry Trial of Thiola EC | $214,313 | 0 | 1 |
| Amendment #1 to Research Agree | $200,000 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Noah Rosenberg, Md, MD | Internal Medicine | Livingston, NJ | $144,075 | $0 |
| Jessica Coleman, M.d, M.D | Nephrology | Beaufort, SC | $91,320 | $0 |
| Andrew Mulberg, M.d, M.D | Pediatrics | Camden, NJ | $85,506 | $0 |
| Abdul Abdellatif, M.d, M.D | Internal Medicine | Webster, TX | $81,119 | $0 |
| Howard Trachtman, Md, MD | Pediatric Nephrology | New York, NY | $80,215 | $0 |
| Ashte Collins, M.d, M.D | Internal Medicine | Washington, DC | $80,028 | $0 |
| Luis Velez, M.d, M.D | Nephrology | San Antonio, TX | $69,526 | $0 |
| Dr. Saravanan Balamuthusamy, M.d, M.D | Internal Medicine | Fort Worth, TX | $69,254 | $0 |
| William White, Md, MD | Hypertension Specialist | Farmington, CT | $69,050 | $0 |
| Anjay Rastogi, Md, MD | Nephrology | Los Angeles, CA | $68,068 | $0 |
| Donald Kohan, Md, MD | Nephrology | Salt Lake City, UT | $67,898 | $0 |
| Andrew Lazar, Md, MD | Nephrology | Beachwood, OH | $65,980 | $0 |
| Dr. Richard Chan, Md, MD | Nephrology | New York, NY | $62,853 | $0 |
| Syeda Ahmad, M.d, M.D | Internal Medicine | Seattle, WA | $62,238 | $0 |
| Arnold Silva, Md, Phd, MD, PHD | Internal Medicine | Meridian, ID | $57,246 | $0 |
| Dr. Derek Larson, M.d, M.D | Nephrology | Creve Coeur, MO | $55,554 | $0 |
| Dr. Yasir Qazi, M.d, M.D | Nephrology | Orange, CA | $54,480 | $0 |
| Dr. James Tumlin, M.d, M.D | Nephrology | Lawrenceville, GA | $53,020 | $0 |
| Shikha Wadhwani, Md, Ms, MD, MS | Nephrology | Galveston, TX | $51,525 | $0 |
| Christopher Gisler, Md, MD | Internal Medicine | Pittsburgh, PA | $50,848 | $0 |
| German Hernandez, M.d, M.D | Internal Medicine | El Paso, TX | $50,585 | $0 |
| Jonathan Hogan, Md, MD | Nephrology | Philadelphia, PA | $47,507 | $0 |
| Richard Lafayette, M.d, M.D | Internal Medicine | Stanford, CA | $44,698 | $0 |
| Dr. Bahar Bastani, Md, MD | Nephrology | St Louis, MO | $44,322 | $0 |
| Dr. Narayan Agrawal, M.d, M.D | Nephrology | Fresh Meadows, NY | $43,787 | $0 |
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. has made $41.4M in payments to 11,855 healthcare providers, recorded across 63,241 transactions in the CMS Open Payments database. In 2024, the company paid $10.4M. The top product by payment volume is Cholbam ($1.7M).
Payments were distributed across 152 medical specialties. The top specialty by payment amount is Nephrology ($2.5M to 3,928 doctors).
Payment categories include: Food & Beverage ($938,824), Consulting ($1.8M), Research ($35.1M), Travel & Lodging ($564,241).
Travere Therapeutics, Inc. is associated with 3 products in the CMS Open Payments database.